Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 3;15(5):279-284.
doi: 10.1158/1940-6207.CAPR-21-0578.

Lessons Learned from the Impact of COVID-19 on NCI-sponsored Cancer Prevention Clinical Trials: Moving Toward Participant-centric Study Designs

Goli Samimi #  1 , Margaret House #  1 , Kelly Benante  2 , Lisa Bengtson  1 , Troy Budd  1 , Bridget Dermody  3 , Katina DeShong  3 , Valerie Dyer  1 , Bruce F Kimler  4 , Vikrant V Sahasrabuddhe  1 , Suzanne Siminski  5 , Leslie G Ford  1 , Eduardo Vilar #  6 , Eva Szabo #  1
Affiliations

Lessons Learned from the Impact of COVID-19 on NCI-sponsored Cancer Prevention Clinical Trials: Moving Toward Participant-centric Study Designs

Goli Samimi et al. Cancer Prev Res (Phila). .

Abstract

The COVID-19 pandemic overloaded health care systems around the globe and brought travel restrictions and other mandates. These effects critically impacted cancer care and conduct of clinical trials, and required medical and research communities to incorporate changes and novel flexible workflows within clinical trials and regulations to improve efficiency. We report the impact of the pandemic on cancer prevention clinical trials managed by the Division of Cancer Prevention within the NCI, focusing on participant-centric, study staff-centric and regulatory elements. Learning lessons from this challenging period, the cancer prevention community has the opportunity to incorporate many of these necessitated novel approaches to future design of clinical trials, to streamline and improve clinical trial efficiency and impact.

PubMed Disclaimer

References

    1. Q&A: Ned Sharpless on COVID-19 and cancer prevention. Cancer Prev Res 2021;14:615–8. - PubMed
    1. Bakouny Z, Paciotti M, Schmidt AL, Lipsitz SR, Choueiri TK, Trinh QD. Cancer screening tests and cancer diagnoses during the COVID-19 pandemic. JAMA Oncol 2021;7:458–60. - PMC - PubMed
    1. Saini KS, de Las Heras B, de Castro J, Venkitaraman R, Poelman M, Srinivasan G, et al. Effect of the COVID-19 pandemic on cancer treatment and research. Lancet Haematol 2020;7:e432–e5-X. - PMC - PubMed
    1. Gaudino M, Arvind V, Hameed I, Di Franco A, Spadaccio C, Bhatt DL, et al. Effects of the COVID-19 pandemic on active non-COVID clinical trials. J Am Coll Cardiol 2020;76:1605–6. - PMC - PubMed
    1. Fontana E, Arkenau HT. Oncology clinical trials during the COVID-19 outbreak: lessons learnt during the crisis and future opportunities. Cancer Treat Rev 2020;88:102047. - PMC - PubMed

Publication types